Skip to content

Menu

Network Sub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact

Search

Close

Enter Search Terms

Sam Herron

ID: 1b83b8f7-2619-30fb-68c4

/

Unclaimed

/

Organization: Goodwin Procter

Fresenius Kabi and Dr. Reddy’s Announce FDA Approval of Rituximab Biosimilar

Big Molecule Watch · August 12, 2026

FDA Advisory Committee Votes in Favor of Moderna Flu Vaccine Benefit-Risk Profile

Big Molecule Watch · July 6, 2026

FDA Approves First Gene Therapy for Rare Pediatric Immune Disorder Severe Leukocyte Adhesion Deficiency Type I

Big Molecule Watch · April 15, 2026

FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)

Big Molecule Watch · April 14, 2026

Formycon Announces New Dupilumab Biosimilar Candidate

Big Molecule Watch · November 25, 2025

Previous

12...5

Next

Claim This Record

Is this your profile? Upgrade to display your full biography, collected works, social connections, practice areas, and more.

Enhance Your Profile

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS

About LexBlog
The Field We Built
Library at LexBlog
Our Beliefs
Our Team
Contact LexBlog

Disclaimer
Editorial Policy
Terms of Service

Get Started
Publishing Solutions
Compass

Submit a Request
Support Center
System Status

Copyright © 2026, LexBlog, Inc. All Rights Reserved.

Law blog design & platform by LexBlog